Skip to main content
PMC home page
eLife logoLink to eLife
. 2023 Sep 22;12:e86043. doi: 10.7554/eLife.86043

The importance of patient-partnered research in addressing long COVID: Takeaways for biomedical research study design from the RECOVER Initiative’s Mechanistic Pathways taskforce

C Kim 1,†, Benjamin Chen 2, Sindhu Mohandas 3,✉, Jalees Rehman 4, Zaki A Sherif 5, K Coombs 6,‡,✉; RECOVER Mechanistic Pathways Task Force, on behalf of the RECOVER Initiative
Editors: Carlos Isales7, Mone Zaidi8
PMCID: PMC10516599  PMID: 37737716

Abstract

The NIH-funded RECOVER study is collecting clinical data on patients who experience a SARS-CoV-2 infection. As patient representatives of the RECOVER Initiative’s Mechanistic Pathways task force, we offer our perspectives on patient motivations for partnering with researchers to obtain results from mechanistic studies. We emphasize the challenges of balancing urgency with scientific rigor. We recognize the importance of such partnerships in addressing post-acute sequelae of SARS-CoV-2 infection (PASC), which includes ‘long COVID,’ through contrasting objective and subjective narratives. Long COVID’s prevalence served as a call to action for patients like us to become actively involved in efforts to understand our condition. Patient-centered and patient-partnered research informs the balance between urgency and robust mechanistic research. Results from collaborating on protocol design, diverse patient inclusion, and awareness of community concerns establish a new precedent in biomedical research study design. With a public health matter as pressing as the long-term complications that can emerge after SARS-CoV-2 infection, considerate and equitable stakeholder involvement is essential to guiding seminal research. Discussions in the RECOVER Mechanistic Pathways task force gave rise to this commentary as well as other review articles on the current scientific understanding of PASC mechanisms.

Note to the reader

With the goal of engaging a broad audience and connecting medical research directly to patient lived experience, we chose to structure this article in two parallel modes: the more objective (plain text) and the more subjective (italicized quotations). The oscillation between a high-level objective view, and personal, subjective narratives attempts to convey a long hauler’s jarring reality. This structure is analogous to our own experience as patient representatives in the NIH-funded RECOVER research initiative. In this capacity, we find ourselves at the intersection of scientific process and personal need, between supporting the processes of rigorous, inclusive, and nuanced scientific research (which takes time), and desiring solutions for ourselves, our families, and the community at large (which we want as soon as possible). We have been granted a window into the complicated process of developing research studies. We witness expert efforts to address an emergent medical condition about which little is understood, even as we struggle with the day-to-day impacts of this very same condition. All the while, we seek understanding and action from our medical providers, research scientists, government leaders, and social groups. By intermingling the juxtaposing objective and subjective perspectives, we hope to elucidate the experience of the ‘patient representative.’ We use the plural form ‘we’ to indicate our own personal experiences and perspectives as patients, but it also conveys many thoughts of the broader community of long COVID patients with whom we are actively engaging.

  • - C. Kim and K. Coombs

Long COVID’s patient community growth followed America’s pandemic response fallout

When the novel coronavirus spread across the globe in the early stages of the SARS-CoV-2 pandemic, people began reporting COVID-19 symptoms persisting beyond the then-expected natural history of two weeks of disease duration. While the emergence of chronically ill patients in past epidemics (Islam et al., 2020) generated little momentum, the sheer numbers of people and repercussions of the SARS-CoV-2 pandemic mobilized masses, including early patients like us. We witnessed the general public’s pandemic fatigue and subsequent increase in high-risk behaviors over time greatly contrasted with our lived experiences. We navigated life-altering illness from a virus that prompted innumerable questions and few answers. Now, chronic symptoms following COVID-19 disease are recognized as post-acute sequelae of SARS-CoV-2 (PASC), and involve ongoing, waxing and waning, or new symptoms, or other health effects occurring after the acute phase of SARS-CoV-2 infection (i.e. present four or more weeks after the acute infection). PASC includes symptoms familiar to many patients as ‘long COVID.’ According to current estimates, such chronic symptoms may affect up to 23 million Americans (U.S. Department of Health and Human Services, 2022a), who also refer to themselves as ‘long haulers.’ Long COVID, a term created by and for patients (Callard and Perego, 2021), is defined as post-infection symptoms or residual illnesses lasting for at least four weeks, endured for a few months to years of progressively severe and debilitating health (U.S. Department of Health and Human Services, 2022b). It may also affect multiple body systems and these systemic manifestations vary over time (U.S. Department of Health and Human Services, 2022b). The prevalence of a persistent post-viral syndrome in such a large patient population could result in an estimated annual loss of 50 billion dollars each year in worker absenteeism (U.S. Department of Health and Human Services, 2022a); a long-term burden on the country’s healthcare system (Maani and Galea, 2020) and a tremendous loss of quality of life. Long COVID is linked to unemployment (Suran, 2023) and may affect up to 16 million working-age Americans (Bach, 2022). Of the estimated 2–4 million people leaving the workforce (Bach, 2022), a significant subset continue to experience persistent long COVID symptoms (Suran, 2023).

In the first two years of the pandemic, we watched mask mandates come and go, vaccines develop and become available, and people isolate and gather again, all while we convalesced intermittently. Despite media reports on new coronavirus variants and the potential to develop long COVID, society’s fatigue with restrictions – in no small part from the whiplash-decision-making (LaFraniere and Weiland, 2022) from political figures and federal agencies – contributed to flouting regulations from the year prior. The clash of affect and reason in risk assessment and resultant desensitization (Slovic and Peters, 2006) toward more than 1.136 million (U.S. Centers for Disease Control and Prevention, 2023) reported American lives lost to date as of July 2023, frustrates and saddens the long COVID community. The growing frustrations of long haulers added to the discouragement from our unattended and overlooked adverse conditions. Some of us acted on our vexation and participated as patient representatives in the RECOVER initiative, part of the National Research Action Plan on Long COVIDhttps://www.zotero.org/google-docs/?5XcINy(U.S. Department of Health and Human Services, 2022a), created from a presidential directive to the Department of Health and Human Services. Some of our drive to become involved with basic research came from being barred from other studies. Many in the ‘first wave’ of the alpha coronavirus variant found themselves unable to participate in research due to stringent protocol criteria: patients’ symptoms would not be recognized as COVID-19-triggered until months later, study time frames could not be changed to include early 2020 SARS-CoV-2-infected patients who did not have a positive antigen test result because testing was scarce at the time, the ICD-10 diagnosis code, U09.9, was released for use well into the pandemic (Pfaff et al., 2023), etc. Regardless of a patient’s ‘study credentials,’ many doctors and researchers were not listening to patients – even when the patients were medical doctors themselves (Yong, 2021).

Patient motivation to partner with researchers

K.C., a patient representative from Vermont, learned about long COVID in August 2020 after having symptoms that started in early March 2020 and suddenly worsened. Simultaneously, her two daughters were also experiencing similar health impacts.

“I initially became interested in the NIH Recover Study because it included children, and I became an early Caregiver Representative in July 2021 during early brainstorming sessions to begin constructing the RECOVER research initiative.

Up until this time, the general world view – including US government and state messaging – had been that children didn't contract SARS-COV-2, or that it was very mild. This had left us out of finding any doctors who had heard of long COVID, and we seemingly continued to fail with our explanations of what this illness looked like for our daughters as often there was no response back to us, as if we had said nothing. It literally felt like no one could hear us, even though we kept trying. I had been seeking support already amongst groups like Body Politic and Long COVID Kids, and I became more convinced that learning more about long COVID through research could really revolutionize new learning about our immune system as well as the potential to help so many other diseases.

I found myself amid a whole large group of researchers, clinicians and other representatives like me who were also concerned; this allowed me to soften, take a breath and realize that after over a full year of my family struggling with debilitating illness while not being believed by practitioners and others, this condition was finally being recognized and legitimized by the NIH.”

Balancing mechanistic pathways research and long haulers’ needs

Often, the first step toward solving a medical challenge like long COVID comes from understanding the pathophysiology of the disease, COVID-19, or the steps the body endures when perturbed by SARS-CoV-2 (NIAID Funding, 2020). By participating in the RECOVER Mechanistic Pathways committee, we are getting a better sense of the complexity of disease mechanisms, which can include persistence of viral molecules, problems with the immune response, or damage to organs (Chen et al., 2023; Mohandas et al., 2023; Sherif et al., 2022) and can persist for months to years after the initial infection. Understanding why the body does not return to an established, healthy equilibrium will allow for the development of potential therapeutics. Unfortunately, many long COVID patients, ourselves included, remain sick, disabled, and removed from our regular occupations and livelihoods to this day. Waiting for safe and effective mechanistic research to inform solutions takes time. Amidst our own uncertainty and declining health, we became and served as experts, consultants, and advocates, and bridges for both the long COVID sufferers and the biomedical research communities. Intellectual partnerships with efforts like the RECOVER initiative enable learning from each other’s perspective. We help biomedical researchers understand and experience the urgency and impact of their research, as well as the importance of building trust in the community. We also help emphasize the need to build on and complement, rather than merely repeat, existing research from similar conditions, such as ME/CFS, Lyme disease, dysautonomia, and other post-viral conditions (Davis et al., 2023).

In turn, we learn of the complexities that come with merging multidisciplinary fields ranging from basic to applied research, and why researchers focus on understanding mechanisms before rushing into using therapeutics with unclear mechanistic basis or dubious outcomes. For example, while the idea of treating COVID-19 with hydroxychloroquine and ivermectin certainly had misinformation and political influences (Knudsen et al., 2023; Barnett et al., 2022), the underlying paucity of mechanistic basis (Barnett et al., 2022; López-Medina et al., 2021; Mitjà et al., 2021; Self et al., 2020) remains a cautious reminder of false hope and potentially worse health outcomes. Several large, carefully crafted, and compelling research studies have since demonstrated the lack of benefit unproven treatments offer for COVID-19. For example, ivermectin showed no measurable reduction in hospitilization rate (Reis et al., 2022; Bramante et al., 2022) nor severity or timeline of COVID-19 symptoms (Naggie et al., 2022; Lim et al., 2022) even at higher doses and treatment duration (Bibbins-Domingo and Malani, 2023). Similarly, proactively taking hydroxychloroquinine did not prevent COVID-19 (Dhibar et al., 2023) nor reduce mortality (World Health Organization, 2023). In the absence of proven treatments and the midst of confusing information, patient-researcher collaborations help us address the question: how do we balance such urgency with scientific rigor?

Same fluctuating symptoms on repeat

“My two daughters and I had multiple new-since-COVID symptoms that kept repeating and disappearing for stretches of time. The recurrence of our initial symptoms along with some new troubling ones made it seem as if we were under attack, and it made me wonder if we were infectious to others, all while my husband continued to remain healthy, which made it all so confusing. We had sore throats, severe stomach aches, headaches, heart palpitations, chest pain, shortness of breath, insomnia, difficulty eating and walking, vision changes, rashes, dizziness, choking throat, painful legs and feet coupled with this new need and desire to lie down, which often brought relief. We would often trend together.

When my mother-in-law visited in Aug 2020 and I told her about what was happening, she said to look up long COVID as it sounded similar. We immediately identified with all the other reports that were being covered in the media (Yong, 2020). I thought this would be a unifying (Collins, 2020) cause everyone could get behind once more people realized that SARS-CoV-2-inflicted disease continued for some (Lowenstein and Davis, 2021). We would want to protect each other and learn more so we could begin to start counting SARS-CoV-2 infections more accurately with robust data, and stop the continuation of spread, symptoms and sequelae.

RECOVER’s initial patient representative-partnered meetings, Phase 1, included the social determinants of health – promising to put equity first with those who have been most affected by SARS-CoV-2 and recognizing the need to rebuild trust within communities. I was hopeful that RECOVER would raise awareness and there would be media attention and public health messaging to follow. As this is a global problem, the NIH’s recognition of the adult, children and pregnancy cohorts being affected by long COVID could lead by example, and also engage other countries to start acknowledging the declining health in their populations.”

A new precedent for patient-centered and patient-partnered research

Historically, healthcare and biomedical research have failed to reflect the diversity of the U.S. population (Bichell, 2015; Cavazzoni et al., 2020; Hermans, 2023). Subsequently, we apply generalizations and assumptions across age, race, ethnic, and social groups despite distinct health or research recruitment needs (Ma et al., 2023; Passmore et al., 2022; Rees et al., 2022). Racism and discrimination in healthcare spans generations and permeates multiple levels, manifesting as chronic stress in an individual (Davies, 2022; Healthy People 2030, 2023), missing public health data points (Krieger, 2021), implicit biases in medical professionals (Davies, 2022), an undiversified healthcare workforce from long-standing discriminatory practices (Blake, 2022; Wilkins et al., 2021), inaccessible medical facilities (Yearby et al., 2022), exclusionary insurance coverage (Artiga et al., 2022; Linke Young, 2020), institutions that perpetuate inequitable systems (Bailey et al., 2017), excessive death and suffering in minority populations (BBC News, 2020; Davies, 2022; Hoffman et al., 2016; Ingraham et al., 2021), and more. Such disparities have persisted with long COVID, disproportionately affecting Brown, Black, Indigenous, and Asian people through higher hospitalization and mortality rates, increased likelihood of developing long COVID and new-onset conditions, and decreased likelihoods of being believed, treated, and diagnosed (Durstenfeld et al., 2023; Jo Hsu, 2022; Khullar et al., 2023; Pfaff et al., 2022; RECOVER Initiative, 2022; Tanne, 2023). Furthermore, when groups often excluded from research or healthcare are incorporated, past mistreatment undermine feeling welcomed and included (BBC News, 2021; Han et al., 2023; Harris, 2016). To address these challenges, healthcare and research can and should increase doctor diversity for improved population health (Snyder et al., 2023), and proactively involve patients at every level of research, from steering committees to community recruitment (Horwitz et al., 2023).

When patients work with researchers to design a large study like RECOVER, having their input contribute to diverse patient recruitment, inclusive eligibility parameters, and accommodations for testing, provides hope that these collaborations represent new precedents in biomedical study design. The RECOVER study has employed a human-centered design (HCD), implementing patient-led research and prioritizing lived experiences (Horwitz et al., 2023; Melles et al., 2021). RECOVER commits to practices like developing culturally responsive and appropriate recruitment materials, communicating findings through seminars like “Understanding Long COVID Across Communities of Color and Those Hit Hardest (RECOVER Initiative, 2022),” and being receptive to the patient community’s emphasis on lived experience by launching projects like the Social, Behavioral, and Economic Impacts of COVID-19 in Vulnerable and Health Disparity Population initiative (National Institutes of Health, 2023). HCD is implemented by many fields such as business and engineering to increase the potential for breakthrough findings. In the context of SARS-COV-2, where nimble yet planned efforts are crucial, HCD encourages patient-centered approaches and guards against repeating research conducted by other post-viral and chronically ill patients with dysautonomia and myalgic encephalomyelitis, or similar phenotypes (Proal and VanElzakker, 2021). Chronic illness patient groups have supported the long COVID community through the uncertainty of new disabilities, the labyrinth of applying for disability benefits, and advocacy efforts. Together, HCD and the solidarity of patient communities create hope that funding may flow toward under-researched areas and that clinical research projects may more actively engage patients as equal stakeholders in the design and implementation.

Healthcare and research efforts are worse off when patients, providers, researchers, or public and private organizations are left in separate silos (White, 2014). The United States’ significant dearth in interoperable data starkly displays the harm of failing to synergize (Mehta and Pandit, 2018). Antiquated, understaffed, and financially constrained, the United States’ public health response abilities are notably deprived. Public health departments largely continue to depend on manual data logging, email, and phone communication. Despite this, their workforce has declined by 15% between 2008 and 2019. Notably, public health makes up a mere 3% of the colossal $3.8 trillion allocated to U.S. healthcare (LaFraniere, 2022). Historic neglect of data interoperability has left a considerable toll, depriving the U.S. of valuable time ahd capabilities during the SARS-CoV-2 pandemic (LaFraniere, 2022). Historic neglect of data interoperability has left a considerable toll, depriving the U.S. of valuable time ahd capabilities during the SARS-COV-2 pandemic (LaFraniere, 2022). Lessons learned from the results of sparse and siloed resources led to the emergence of a new trajectory to advance research. The RECOVER initiative strives to follow this new path by combining efforts, acknowledging the intrinsic worth of every stakeholder.

Understanding long COVID and assessing need for care

“I was so inspired by some of the ideas from the early meeting for the RECOVER Initiative in 2021, but at the same time I recognized that a National response would take a long time to launch and most likely would not reach the rural communities near me. I wondered if we could initiate a registry for long COVID cases in Vermont, and specifically within my county. I knew that a wave of illnesses impacted my town in late February/early March 2020, and as Vermont has a lot of small towns, I was concerned there were more individuals experiencing illness like us. Individuals who required comprehensive attention that could benefit from working together to share information and resources. I met with my state senator to see if he could reach out to local doctors and community health leaders to see what they had been experiencing and how to start assessing the need for care. I joined the COVID-19 Longhauler Advocacy Project (C-19LAP) in late 2020 and became increasingly interested in learning more about the Vermont Government and doing advocacy work. As individual states began leading the pandemic response within their borders, this work became even more important. I gave my personal narrative at Advocacy Days (Solve M.E. Advocacy Week, 2021), an event in which Solve ME included and equipped Longhaulers to share their stories amongst caretakers and people with ME/CFS. We met with Legislative Assistants to US Senators and Representatives in our states hoping to raise awareness. Giving my personal narrative on Advocacy Days in 2021 and 2022 was a powerful experience for me, where I learned about the importance of story and active listening in this new context. I learned that it is ok for me to demand a space to tell my story in whatever way I am comfortable, and that I have things to offer as well as a new outlet for expressing my challenging experiences.”

Long COVID’s uncertainty and the freedom of simply asking: why?

The novel coronavirus presents numerous ambiguous challenges, spanning from pinpointing the underlying causes to potential treatments. Acknowledging our lack of answers to various queries can, in a sense, offer a liberating perspective. As early long haulers, it is wearisome to constantly live with waxing and waning symptoms, trying different medications, and navigating an altered life course as we go. All the while, some medical providers feign omnipresent prowess and then offer little resolution. Irrespective of an individual's pre-existing health status, a fundamental question arises: why do some people remain chronically ill? How does this virus affect seemingly every organ system and cause so many disabilities? Conversely, the question arises as to why certain individuals effectively eliminate the infection without symptoms or significant complications. Could it be the host genetics that is implicated in differential immunological responses to infection and disease progression (Augusto et al., 2023)? We anticipate the RECOVER initiative, along with other biomedical researchers, will shed light on these inquiries and more. Partnering with researchers helps us reframe the endless uncertainty to endless potential answers. Investigating possible mechanistic pathways to find explanations, or actively searching for explanations in uncertain times, can reduce fear and offer hope to patients in finding resolutions and the next steps.

Inability to participate in research and long COVID clinics

“Our story is about the fight for legitimacy and validity as patients seeking care, a status that has remained elusive throughout the epidemic and pandemic phases. With my past work as an acupuncturist, I have listened to many reports from patients about barriers to receiving effective Western medical care. I also decided to go to acupuncture school in 1997 after becoming sick from a parasitic infection, Ascaris. I started having constant headaches and nausea and sought out an acupuncturist then. It wasn't a magic cure in the sense that I was suddenly better – as it took many more years to fully recover – but I did begin a new love for this type of medicine, as I felt less turmoil and more ease internally with Chinese Medicine in a way that I hadn’t experienced before, all while learning new ways to interpret health and disease.

Years later, soon after moving to Vermont, one of my daughters became sick with acute to chronic Lyme disease when she was 6, and it took 1.5 years to recover. My family learned that illness has its own timeline, regardless of how much time is spent chasing doctors and trying hard to get better. We were left to figure it out mostly on our own, and I am certain that this second hit from SARS-CoV-2 was exactly what my daughter didn't need, even with being well for 2 years in between.

It has risen to another level of difficulty to be on the other side of wellness, with 3 out of 4 of our immediate family becoming suddenly chronically ill and disabled from a new airborne virus, while few doctors have been trained to recognize or treat post viral illnesses; it has been an impossible task on every front as complex, invisible diseases are too easily dismissed in Western medicine.

The lack of testing and knowledge at the beginning of the pandemic really harmed our ability to seek care later with any credibility. When we began seeking guidance for our various emerging symptoms, I made sure to talk about SARS-CoV-2 and long COVID at every medical appointment with hopes to get this information in our doctor’s notes from the beginning. I divided up our medical needs into what were our top 3 most debilitating problems, and sought out referrals to those specialists. Three and a half years after our initial onset of continual symptoms, we are still working on making a team for each of us that is respectful and supportive while we continue to wait for more answers and therapeutics.”

Existing challenges to PASC

While basic research is underway, multiple challenges to PASC remain. For example, limited public understanding, inconsistent and highly demanded disability support, and complicated ways to translate scientific findings (COVID-19 Longhauler Advocacy Project, 2022; Department of Health and Human Services, 2022; McCorkell, 2023; OPEN LETTER | COVID-19 Longhauler Advocacy Project | C-19 LAP, 2022). From May 21 to June 10, 2021, a survey of nearly 2000 American adults found that over 30% of Americans were unaware of long COVID and 39% remained unconcerned after reading a description of the condition (Resolve to Save Lives, V. S, 2021). On a global level, Google search trends for the term ‘COVID-19’ dominated online interest in 2020 and yielded significant interest since then, suggesting common awareness of SARS-CoV-2, but far smaller search interest in ‘long COVID’ and related terms (Kaatz et al., 2022). Despite immense PASC patient numbers, the far-reaching impacts of long COVID (U.S. Department of Health and Human Services, 2022a), and general awareness of the condition’s catalyst, a significant portion of the general populace is not aware or attentive to this issue. This could reduce the likelihood of public health communication within communities and common knowledge of pertinent research studies, such as RECOVER, that may be recruiting locally.

For those living with PASC, despite awareness of the condition and possible knowledge of research studies, the need to acquire disability support often takes precedence. The impact of disability support for long haulers is significantly influenced by their social determinants of health (Social Determinants of Health, 2022), especially the structural and individual discriminatory conditions like housing and education segregation, racism, and ableism, that affect resource access. America’s already strained social safety net (Rowland, 2022) with claim approval dependent on meeting documented loss of function criteria, often in the form of abnormal test results, means many newly disabled long haulers struggle to obtain financial benefits and workplace accommodations (Stead Sellers, 2022). As of March 2022, the Social Security Administration received approximately 23,000 disability applications related to COVID (Rowland, 2022), representing a fraction of 1% of total annual applications. In 2020 and 2021, Social Security’s Disability program received 1,838,893 and 1,820,282 applications for disabled-worker benefits, respectively, approving less than 36% of all applications each year; a declining approval trend since 2009 (U.S. Society Security Administration, 2022). The demand for existing benefits among existing disabled and chronically ill populations (Stead Sellers, 2022) only increased with the pandemic’s onset, leaving many long haulers in uncertain financial and medical situations. Additionally, America’s laws reside in health, education, and workforce sector silos (Sperling, 2020; Wagner Mery, 2022) that can delay a patient’s journey to obtain necessary support and resources by years (Wagner Mery, 2022). While experts and experienced disability advocates view the long COVID community as a potential changemaker in America’s disability infrastructure (Stead Sellers, 2022) due to sheer population prevalence, these changes will take time.

Time may be the most acutely felt pain for patients, providers, and researchers in addressing long COVID. Support for basic research on long COVID in America is moving slowly (Wadman, 2022) and with aversion to risk (Kaiser, 2022), as the National Institutes of Health aims to carefully balance speed and scientific rigor to allocate taxpayer money into research grants that return on investment. While other countries such as the United Kingdom moved swiftly to fund 15 long COVID clinical trials by July 2021 (Wadman, 2022), as of February 2022, the United States had only funded 8 of over 200 long COVID clinical trials (The Rockefeller Foundation et al., 2022). As scientific institutions weigh research best practices, data-driven healthcare, and treatment urgency to clarify optimal patient care, caregivers and patients experience a stressful reality. Patients desperate for symptom relief who have extra resources and time are turning to the growing market of businesses and private practices with mixed results. Many go through trial and error with treatments; an experience akin to guessing as treating long COVID may require tailored care to a specific phenotype (Shaffer, 2022). Anecdotally from online patient group discussions, those willing and able to try unsubstantiated treatments report variable degrees of relief or symptom progressions based on inumerable factors. Groups that allow sharing of medication or treatment information often emphasize the patient experience and the supervision of a doctor. However, as a result of many companies taking advantage of patients and profiteering from the mass suffering of long COVID, other groups are strictly moderated and prohibit treatment discussion.

Further exacerbating PASC’s time pressure is the NIH’s historic underfunding of overlapping illnesses with potential post-viral origins that have extremely similar phenotypes to long COVID (Komaroff, 2019). If research for diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which affects an estimated 1–2.5 million Americans as of 2020 (Mirin et al., 2020), was appropriately funded in years past according to disease burden (Green et al., 2015; Mirin et al., 2020), we would likely have more insight and progress on addressing long COVID today. Long COVID patient advocacy grew under the guidance of and commonalities with existing chronic illness communities. Chronic underfunding of ME/CFS (Mirin et al., 2020) and other post-viral illness research such as dysautonomias, as well as neglecting existing research on such topics (Proal and VanElzakker, 2021), undermines efforts to address long COVID. The slow pace of funding and establishing foundational research for post-viral illnesses and RECOVER’s focus on data collection concerns patients and doctors that time is not being used efficiently. While clinical trials for therapeutics are in the works, their pace feels especially slow, knowing private-public partnerships such as those seen in developing COVID-19 vaccines (Cohrs, 2022) can be nimble and ground-breaking. We look forward to mechanistic research on COVID-19 building a strong foundation for therapeutics to build on, but in the meantime, we must live with new disabilities and different qualities of life. Constructing and translating PASC research, balancing scientific rigor and legitimate stakeholder concerns, and fielding low public awareness and disability support for long COVID unfortunately give rise to the perception that we are building the plane as it is moving down the runway.

Patient-partnered research is humanizing and meaningful

“There were some days where I wondered who I was after becoming a COVID long hauler in early 2020. For months, I lost the ability to walk, smell, breathe, read, write, communicate, cook, and sleep. Medical providers eventually diagnosed me with COVID-19-triggered functional disorders and syndromes that many tests failed to capture as abnormal. Instead of new adventures soon after graduating college, I had my 24th birthday alone in a walker and was terminated from my first job as an engineer. I realized I valued myself based on my skills and my identities, when long COVID took so many and I didn’t know what I had left. For some time, I couldn’t name what I was good at or what I liked because my numerous new disabilities required me to drastically change my lifestyle. Over three years after my initial April 2020 infection, I am still disabled and live with significant changes in my daily life. I have experienced multiple symptom fluctuations frustrations, difficult side effects from treatments, and am now at a place where I am tired of trying potential cures. I find it more worth my time and effort to focus on accessibility, accommodations, and the human, rather than the technical, side. While I am not back to my previous functioning and still look forward to future therapeutics that may ease suffering from long COVID, partnering with RECOVER to support patient-centered mechanistic research feels meaningful. – C.K.”

Future impact

While significant challenges to understanding and treating long COVID exist, such as low public and medical awareness, historic racial disparities in healthcare access, chronic underfunding of post viral illness research, and time urgency, collaborative and mutually beneficial patient-provider-researcher relationships can play a central role in achieving success. For example, grassroots, patient-partnered organizations and research groups have garnered increased awareness of postviral conditions in communities of color and greater attention to ameliorating racial biases in healthcare (Bright Star Community Outreach, 2023; C19LAP, 2023; Dysautonomia International, 2023; Illinois Unidos, 2023; Jason and Torres, 2022; Long-COVID Alliance, 2023; Massachussetts General Hospital, 2022; #MEAction, 2023; PLRC, 2023; Shaw et al., 2019,Solve M.E, 2023; The Ehlers-Danlos Society, 2023). The importance of long COVID has also been reflected in proposed legislation, a National Academies committee to examine the working definition, and a HHS long COVID report naming racial disparities as a key obstacle to understanding and treating long COVID (Department of Health and Human Services, n.d.; Eldahshoury, 2023; National Academies of Science, Enginering, and Medicine, 2023; Kaine, 2023). This in turn has contributed to meaningful efforts in addressing the racial disparity of rare and chronic postviral-associated diagnoses in people of color (dforsythe, 2020), particularly following long COVID (Khullar et al., 2023). Experts recognize that the typical approach to describing a new disease based on a constellation of symptoms is not fruitful for understanding long COVID (Cooney, 2022). Expertise on long COVID falls within the patient realm as well. Research institutions are challenged with a new precedent following the COVID-19 pandemic to equitably partner with patients in research efforts. We look forward to RECOVER and other biomedical studies contributing to an increased understanding of and potential treatments for PASC. Investing in long COVID and related post-viral illness research in concert with sustainable accessibility support for disabled and chronically ill patients will result in long-term benefits for populations with unmet needs beyond long COVID patients.

A note from the medical co-authors

In the fight against HIV/AIDS, Dr. Anthony Fauci has acknowledged the central role that patient activists played in pushing for faster and innovative trial designs when they demanded a seat at the table. Similarly, in the fight against long COVID, the engagement of patient representatives as research partners is needed to press for systematic trials and to help focus research on involving patients in much needed trials. Partnerships with patient advocacy groups are also needed to communicate the urgent need for resources that improve quality of life until more definitive treatments for long COVID are identified.

Acknowledgements

This work was supported by the Researching Covid to Enhance Recovery (RECOVER) Initiative (OT2HL161847-01) through the American Rescue Plan Act of 2021 (Sec. 2401). We would like to thank the National Community Engagement Group (NCEG), all patient, caregiver, and community representatives, and all the participants enrolled in the RECOVER Initiative. This work was made possible through support from the National Institutes of Health, New York University Langone Health, Research Triangle Institute, and the RECOVER Initiative’s Mechanistic Pathways task force. Significant thanks to Drs. Benjamin Chen, Sindhu Mohandas, Jalees Rehman, and Zaki Sherif for consulting and exemplifying true patient-provider-researcher partnership. This content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH, or other funders. Funding: This research was funded by the National Institutes of Health (NIH) Agreement OTA OT2HL161847 (contract number 01) as part of the RECOVER research program. RECOVER seeks to understand, treat, and prevent the PASC. For more information on RECOVER, visit https://recovercovid.org/

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Sindhu Mohandas, Email: smohandas@chla.usc.edu.

K Coombs, Email: vtlonghaulers@gmail.com.

Carlos Isales, Augusta University, United States.

Mone Zaidi, Icahn School of Medicine at Mount Sinai, United States.

RECOVER Mechanistic Pathways Task Force:

Boris Julg, Steven B Bradfute, Christian R Gomez, Thomas J Connors, Timothy J Heinrich, W Brian Reeves, Prasanna Jagannathan, Christian Bime, Erin Burke Quinlan, Michael A Portman, and Maria Laura Gennaro

Funding Information

This paper was supported by the following grant:

  • National Institutes of Health OT2HL161847 (contract number 01) to C Kim, K Coombs.

Additional information

Competing interests

No competing interests declared.

Author contributions

Conceptualization, Resources, Writing – original draft, Writing – review and editing.

Conceptualization, Supervision, Writing – review and editing.

Conceptualization, Supervision, Writing – review and editing.

Conceptualization, Resources, Supervision, Writing – review and editing.

Conceptualization, Writing – review and editing.

Conceptualization, Resources, Writing – original draft, Writing – review and editing.

Conceptualization.

References

  1. #MEAction Long COVID & ME: Understanding the Connection. #MEAction Network. 2023. [July 19, 2023]. https://www.meaction.net/long-covid-me-understanding-the-connection/
  2. Artiga S, Hill L, Damico A. Health Coverage by Race and Ethnicity, 2010-2021. 2022. [December 20, 2022]. https://www.kff.org/racial-equity-and-health-policy/issue-brief/health-coverage-by-race-and-ethnicity/
  3. Augusto DG, Murdolo LD, Chatzileontiadou DSM, Sabatino JJ, Yusufali T, Peyser ND, Butcher X, Kizer K, Guthrie K, Murray VW, Pae V, Sarvadhavabhatla S, Beltran F, Gill GS, Lynch KL, Yun C, Maguire CT, Peluso MJ, Hoh R, Henrich TJ, Deeks SG, Davidson M, Lu S, Goldberg SA, Kelly JD, Martin JN, Vierra-Green CA, Spellman SR, Langton DJ, Dewar-Oldis MJ, Smith C, Barnard PJ, Lee S, Marcus GM, Olgin JE, Pletcher MJ, Maiers M, Gras S, Hollenbach JA. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. 2023;620:128–136. doi: 10.1038/s41586-023-06331-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bach K. New data shows long Covid is keeping as many as 4 million people out of work. 2022. [August 24, 2022]. https://www.brookings.edu/research/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/
  5. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389:1453–1463. doi: 10.1016/S0140-6736(17)30569-X. [DOI] [PubMed] [Google Scholar]
  6. Barnett ML, Gaye M, Jena AB, Mehrotra A. Association of county-level prescriptions for hydroxychloroquine and ivermectin with county-level political voting patterns in the 2020 us presidential election. JAMA Internal Medicine. 2022;182:452–454. doi: 10.1001/jamainternmed.2022.0200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. BBC News Black US doctor dies of Covid alleging racist hospital care. BBC News. 2020. [December 24, 2020]. https://www.bbc.com/news/world-us-canada-55443339
  8. BBC News Covid: Black leaders fear racist past feeds mistrust in vaccine. BBC News. 2021. [May 5, 2021]. https://www.bbc.com/news/health-56813982
  9. Bibbins-Domingo K, Malani PN. At a higher dose and longer duration, Ivermectin still not effective against COVID-19. JAMA. 2023;329:897–898. doi: 10.1001/jama.2023.1922. [DOI] [PubMed] [Google Scholar]
  10. Bichell RE. Clinical Trials Still Don’t Reflect The Diversity Of America. NPR. 2015. [July 19, 2023]. https://www.npr.org/sections/health-shots/2015/12/16/459666750/clinical-trials-still-dont-reflect-the-diversity-of-america
  11. Blake A. The Journey of the Underrepresented: The History of Exclusion in the Health Care Field. 2022. [July 19, 2023]. https://www.neomed.edu/news/the-journey-of-the-underrepresented-the-history-of-exclusion-in-the-health-care-field/
  12. Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA, COVID-OUT Trial Team Randomized trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. The New England Journal of Medicine. 2022;387:599–610. doi: 10.1056/NEJMoa2201662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bright Star Community Outreach Bright Star Community Outreach. 2023. [July 19, 2023]. https://www.brightstarcommunityoutreach.com
  14. C19LAP HOME | COVID-19 Longhauler Advocacy Project | C-19 LAP. 2023. [July 19, 2023]. https://www.longhauler-advocacy.org
  15. Callard F, Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cavazzoni P, Anagnostiadis E, Ph R, Lolic M. 2020 Drug Trials Snapshots Summary Report. US Food and Drug Administration; 2020. https://www.fda.gov/media/145718/download [Google Scholar]
  17. Chen B, Julg B, Mohandas S, Bradfute SB, RECOVER Mechanistic Pathways Task Force Viral persistence, reactivation, and mechanisms of long COVID. eLife. 2023;12:e86015. doi: 10.7554/eLife.86015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cohrs R. A slow-moving glacier’: NIH’s sluggish and often opaque efforts to study long Covid draw patient, expert ire. 2022. [March 29, 2022]. https://www.statnews.com/2022/03/29/nih-long-covid-sluggish-study/
  19. Collins DF. Citizen scientists take on the challenge of long-haul COVID-19. 2020. [September 3, 2020]. https://directorsblog.nih.gov/2020/09/03/citizen-scientists-take-on-the-challenge-of-long-haul-covid-19/
  20. Cooney E. There’s no one long Covid’: Experts struggle to make sense of the continuing mystery. 2022. [July 22, 2022]. https://www.statnews.com/2022/07/22/theres-no-one-long-covid-experts-struggle-to-make-sense-of-the-continuing-mystery/
  21. COVID-19 Longhauler Advocacy Project A Comprehensive & Systematic Approach to Planning & Desired Outcomes for the Long Covid Community. 2022. [October 20, 2022]. https://docs.google.com/document/d/1aTXH7PxUTcyP7zx325vxUvZ52lkKeG0oZ9cKu-mtN0M/edit?usp=embed_facebook
  22. Davies D. "1619 Project” journalist lays bare why Black Americans “live sicker and die quicker". NPR. 2022. [June 14, 2022]. https://www.npr.org/sections/health-shots/2022/06/14/1103935147/linda-villarosa-under-the-skin-racism-healthcare
  23. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews. Microbiology. 2023;21:133–146. doi: 10.1038/s41579-022-00846-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Department of Health and Human Services COVID.gov/longcovid—Virus that causes COVID-19 can experience long-term effects from their infection. 2022. [October 20, 2022]. https://www.covid.gov/longcovid
  25. dforsythe Black Women’s Health Imperative Announces New Rare Disease Diversity Coalition. 2020. [May 29, 2020]. https://bwhi.org/2020/05/29/black-womens-health-imperative-announces-new-rare-disease-diversity-coalition/
  26. Dhibar DP, Arora N, Chaudhary D, Prakash A, Medhi B, Singla N, Mohindra R, Suri V, Bhalla A, Sharma N, Singh MP, Lakshmi PVM, Goyal K, Ghosh A. The “myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19” is far from reality. Scientific Reports. 2023;13:378. doi: 10.1038/s41598-022-26053-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Durstenfeld MS, Peluso MJ, Peyser ND, Lin F, Knight SJ, Djibo A, Khatib R, Kitzman H, O’Brien E, Williams N, Isasi C, Kornak J, Carton TW, Olgin JE, Pletcher MJ, Marcus GM, Beatty AL. Factors associated with long COVID symptoms in an online Cohort Study. Open Forum Infectious Diseases. 2023;10:ofad047. doi: 10.1093/ofid/ofad047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Dysautonomia International Dysautonomia International: Coronavirus & Dysautonomia. 2023. [July 19, 2023]. http://www.dysautonomiainternational.org/page.php?ID=227
  29. Eldahshoury M. As COVID Emergency Ends, Pressley, Beyer, Blunt Rochester Unveil Bill to Support COVID Long Haulers. 2023. [May 11, 2023]. https://pressley.house.gov/2023/05/11/as-covid-emergency-ends-pressley-beyer-blunt-rochester-unveil-bill-to-support-covid-long-haulers/
  30. Green CR, Cowan P, Elk R, O’Neil KM, Rasmussen AL. National institutes of health pathways to prevention workshop: Advancing the research on myalgic encephalomyelitis/chronic fatigue syndrome. Annals of Internal Medicine. 2015;162:860–865. doi: 10.7326/M15-0338. [DOI] [PubMed] [Google Scholar]
  31. Han S, Riddell JR, Piquero AR. Anti-Asian American hate crimes spike during the early stages of the COVID-19 Pandemic. Journal of Interpersonal Violence. 2023;38:3513–3533. doi: 10.1177/08862605221107056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Harris R. Medical Studies Involving Children Often Go Unpublished. NPR. 2016. [July 19, 2023]. https://www.npr.org/sections/health-shots/2016/08/04/488708038/medical-studies-involving-children-often-go-unpublished
  33. Healthy People 2030 Discrimination—Healthy People 2030 | health.gov. 2023. [July 19, 2023]. https://health.gov/healthypeople/priority-areas/social-determinants-health/literature-summaries/discrimination
  34. Hermans A. How Can Research Better Represent People with Disabilities? Urban Institute. 2023. [January 3, 2023]. https://www.urban.org/urban-wire/how-can-research-better-represent-people-disabilities
  35. Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. PNAS. 2016;113:4296–4301. doi: 10.1073/pnas.1516047113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Horwitz LI, Thaweethai T, Brosnahan SB, Cicek MS, Fitzgerald ML, Goldman JD, Hess R, Hodder SL, Jacoby VL, Jordan MR, Krishnan JA, Laiyemo AO, Metz TD, Nichols L, Patzer RE, Sekar A, Singer NG, Stiles LE, Taylor BS, Ahmed S, Algren HA, Anglin K, Aponte-Soto L, Ashktorab H, Bassett IV, Bedi B, Bhadelia N, Bime C, Bind M-AC, Black LJ, Blomkalns AL, Brim H, Castro M, Chan J, Charney AW, Chen BK, Chen LQ, Chen P, Chestek D, Chibnik LB, Chow DC, Chu HY, Clifton RG, Collins S, Costantine MM, Cribbs SK, Deeks SG, Dickinson JD, Donohue SE, Durstenfeld MS, Emery IF, Erlandson KM, Facelli JC, Farah-Abraham R, Finn AV, Fischer MS, Flaherman VJ, Fleurimont J, Fonseca V, Gallagher EJ, Gander JC, Gennaro ML, Gibson KS, Go M, Goodman SN, Granger JP, Greenway FL, Hafner JW, Han JE, Harkins MS, Hauser KSP, Heath JR, Hernandez CR, Ho O, Hoffman MK, Hoover SE, Horowitz CR, Hsu H, Hsue PY, Hughes BL, Jagannathan P, James JA, John J, Jolley S, Judd SE, Juskowich JJ, Kanjilal DG, Karlson EW, Katz SD, Kelly JD, Kelly SW, Kim AY, Kirwan JP, Knox KS, Kumar A, Lamendola-Essel MF, Lanca M, Lee-Lannotti JK, Lefebvre RC, Levy BD, Lin JY, Logarbo BP, Logue JK, Longo MT, Luciano CA, Lutrick K, Malakooti SK, Mallett G, Maranga G, Marathe JG, Marconi VC, Marshall GD, Martin CF, Martin JN, May HT, McComsey GA, McDonald D, Mendez-Figueroa H, Miele L, Mittleman MA, Mohandas S, Mouchati C, Mullington JM, Nadkarni GN, Nahin ER, Neuman RB, Newman LT, Nguyen A, Nikolich JZ, Ofotokun I, Ogbogu PU, Palatnik A, Palomares KTS, Parimon T, Parry S, Parthasarathy S, Patterson TF, Pearman A, Peluso MJ, Pemu P, Pettker CM, Plunkett BA, Pogreba-Brown K, Poppas A, Porterfield JZ, Quigley JG, Quinn DK, Raissy H, Rebello CJ, Reddy UM, Reece R, Reeder HT, Rischard FP, Rosas JM, Rosen CJ, Rouphael NG, Rouse DJ, Ruff AM, Saint Jean C, Sandoval GJ, Santana JL, Schlater SM, Sciurba FC, Selvaggi C, Seshadri S, Sesso HD, Shah DP, Shemesh E, Sherif ZA, Shinnick DJ, Simhan HN, Singh U, Sowles A, Subbian V, Sun J, Suthar MS, Teunis LJ, Thorp JM, Ticotsky A, Tita ATN, Tragus R, Tuttle KR, Urdaneta AE, Utz PJ, VanWagoner TM, Vasey A, Vernon SD, Vidal C, Walker T, Ward HD, Warren DE, Weeks RM, Weiner SJ, Weyer JC, Wheeler JL, Whiteheart SW, Wiley Z, Williams NJ, Wisnivesky JP, Wood JC, Yee LM, Young NM, Zisis SN, Foulkes AS. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design. PLOS ONE. 2023;18:e0286297. doi: 10.1371/journal.pone.0286297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Illinois Unidos Home. Illinois Unidos. 2023. [July 19, 2023]. https://illinoisunidos.com/
  38. Ingraham NE, Purcell LN, Karam BS, Dudley RA, Usher MG, Warlick CA, Allen ML, Melton GB, Charles A, Tignanelli CJ. Racial and ethnic disparities in Hospital admissions from COVID-19: determining the impact of Neighborhood Deprivation and Primary Language. Journal of General Internal Medicine. 2021;36:3462–3470. doi: 10.1007/s11606-021-06790-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Islam MF, Cotler J, Jason LA. Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue. 2020;8:61–69. doi: 10.1080/21641846.2020.1778227. [DOI] [Google Scholar]
  40. Jason LA, Torres C. Differences in symptoms among Black and White Patients with ME/CFS. Journal of Clinical Medicine. 2022;11:6708. doi: 10.3390/jcm11226708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Jo Hsu V. Boston Globe. 2022. [December 1, 2022]. https://www.bostonglobe.com/2022/12/01/opinion/we-might-be-over-pandemic-its-not-over-us/
  42. Kaatz M, Springer S, Schubert R, Zieger M. Representation of long COVID syndrome in the awareness of the population is revealed by Google Trends analysis. Brain, Behavior, & Immunity - Health. 2022;22:100455. doi: 10.1016/j.bbih.2022.100455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Kaine T. Text - S.801 - 118th Congress (2023-2024): CARE for Long COVID Act (2023-03-15) [Legislation] 2023. [March 15, 2023]. http://www.congress.gov/bill/118th-congress/senate-bill/801/text
  44. Kaiser J. The U.S. just created a big new biomedical research agency. But questions remain. 2022. [March 15, 2022]. https://www.science.org/content/article/u-s-just-created-big-new-biomedical-research-agency-questions-remain
  45. Khullar D, Zhang Y, Zang C, Xu Z, Wang F, Weiner MG, Carton TW, Rothman RL, Block JP, Kaushal R. Racial/Ethnic Disparities in Post-acute Sequelae of SARS-CoV-2 Infection in New York: an EHR-Based Cohort Study from the RECOVER Program. Journal of General Internal Medicine. 2023;38:1127–1136. doi: 10.1007/s11606-022-07997-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Knudsen J, Perlman-Gabel M, Uccelli IG, Jeavons J, Chokshi DA. Combating misinformation as a core function of Public Health. NEJM Catalyst. 2023;4 doi: 10.1056/CAT.22.0198. [DOI] [Google Scholar]
  47. Komaroff A. Advances in understanding the Pathophysiology of Chronic Fatigue Syndrome| Neurology | JAMA | JAMA Network. 2019. [July 5, 2019]. https://jamanetwork.com/journals/jama/article-abstract/2737854?resultClick=1 [DOI] [PubMed]
  48. Krieger N. Structural Racism, Health Inequities, and the two-edged Sword of Data: structural problems require structural solutions. Frontiers in Public Health. 2021;9:655447. doi: 10.3389/fpubh.2021.655447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. LaFraniere S. Very Harmful’ Lack of Data Blunts U.S Response to Outbreaks. The New York Times. 2022. [September 20, 2022]. https://www.nytimes.com/2022/09/20/us/politics/covid-data-outbreaks.html
  50. LaFraniere S, Weiland N. Walensky, Citing Botched Pandemic Response, Calls for C.D.C Reorganization. The New York Times. 2022. [August 17, 2022]. https://www.nytimes.com/2022/08/17/us/politics/cdc-rochelle-walensky-covid.html
  51. Lim SCL, Hor CP, Tay KH, Mat Jelani A, Tan WH, Ker HB, Chow TS, Zaid M, Cheah WK, Lim HH, Khalid KE, Cheng JT, Mohd Unit H, An N, Nasruddin AB, Low LL, Khoo SWR, Loh JH, Zaidan NZ, Ab Wahab S, Song LH, Koh HM, King TL, Lai NM, Chidambaram SK, Peariasamy KM, I-TECH Study Group Efficacy of Ivermectin Treatment on Disease Progression among Adults with Mild to Moderate COVID-19 and Comorbidities: the I-TECH Randomized Clinical Trial. JAMA Internal Medicine. 2022;182:426–435. doi: 10.1001/jamainternmed.2022.0189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Linke Young C. There are clear, race-based inequalities in health insurance and health outcomes. 2020. [July 12, 2023]. https://www.brookings.edu/articles/there-are-clear-race-based-inequalities-in-health-insurance-and-health-outcomes/
  53. Long-COVID Alliance Partners. Long-COVID Alliance. 2023. [July 19, 2023]. https://longcovidalliance.org/home/partners/
  54. López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, Díazgranados JA, Oñate JM, Chavarriaga H, Herrera S, Parra B, Libreros G, Jaramillo R, Avendaño AC, Toro DF, Torres M, Lesmes MC, Rios CA, Caicedo I. Effect of Ivermectin on time to resolution of symptoms among adults with Mild COVID-19: a randomized clinical trial. JAMA. 2021;325:1426–1435. doi: 10.1001/jama.2021.3071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Lowenstein F, Davis H. Opinion | Long Covid Is Not Rare. It’s a Health Crisis The New York Times. 2021. [March 17, 2021]. https://www.nytimes.com/2021/03/17/opinion/long-covid.html
  56. Ma S, Yu J, Qin X, Liu J. Current status and challenges in establishing reference intervals based on real-world data. Critical Reviews in Clinical Laboratory Sciences. 2023;60:427–441. doi: 10.1080/10408363.2023.2195496. [DOI] [PubMed] [Google Scholar]
  57. Maani N, Galea S. COVID-19 and underinvestment in the Public Health Infrastructure of the United States. The Milbank Quarterly. 2020;98:250–259. doi: 10.1111/1468-0009.12463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Massachussetts General Hospital Greater Boston COVID recovery cohort Joins national effort to study long-term effects of COVID-19. 2022. [July 19, 2023]. https://www.massgeneral.org/news/press-release/greater-boston-covid-recovery-cohort?utm_source=ACC+Communications&utm_campaign=60bdab5a5f-EMAIL_CAMPAIGN_2022_11_22_08_24&utm_medium=email&utm_term=0_-60bdab5a5f-%5BLIST_EMAIL_ID%5D
  59. McCorkell L. 3 Years Into Long COVID: Where Do We Go From Here? Medscape. 2023. [June 29, 2023]. https://www.medscape.com/viewarticle/993827
  60. Mehta N, Pandit A. Concurrence of big data analytics and healthcare: a systematic review. International Journal of Medical Informatics. 2018;114:57–65. doi: 10.1016/j.ijmedinf.2018.03.013. [DOI] [PubMed] [Google Scholar]
  61. Melles M, Albayrak A, Goossens R. Innovating health care: key characteristics of human-centered design. International Journal for Quality in Health Care. 2021;33:37–44. doi: 10.1093/intqhc/mzaa127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Mirin AA, Dimmock ME, Jason LA. Research update: the relation between ME/CFS disease burden and research funding in the USA. Work. 2020;66:277–282. doi: 10.3233/WOR-203173. [DOI] [PubMed] [Google Scholar]
  63. Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B, BCN-PEP-CoV2 Research Group A cluster-randomized trial of Hydroxychloroquine for prevention of Covid-19. The New England Journal of Medicine. 2021;384:417–427. doi: 10.1056/NEJMoa2021801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Mohandas S, Jagannathan P, Henrich TJ, Sherif ZA, Bime C, Quinlan E, Portman MA, Gennaro M, Rehman J, RECOVER Mechanistic Pathways Task Force Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC) eLife. 2023;12:e86014. doi: 10.7554/eLife.86014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators Effect of Ivermectin vs Placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;328:1595–1603. doi: 10.1001/jama.2022.18590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. National Academies of Science, Enginering, and Medicine Examining the Working Definition for Long COVID - Workshop | National Academies. Symposium of Long COVID: Examining the Working Definition. 2023. [June 23, 2023]. https://www.nationalacademies.org/event/06-22-2023/examining-the-working-definition-for-long-covid-workshop
  67. National Institutes of Health NIH COVID-19 Research. 2023. [July 20, 2023]. https://covid19.nih.gov/news-and-stories/covid19-ripple-effects
  68. NIAID Funding What is a mechanistic study?” | NIH: National Institute of Allergy and Infectious Diseases. 2020. [May 20, 2020]. https://www.niaid.nih.gov/grants-contracts/what-mechanistic-study
  69. OPEN LETTER | COVID-19 Longhauler Advocacy Project | C-19 LAP Covid 19 Longhauler. 2022. [October 20, 2022]. https://www.longhauler-advocacy.org/open-letter
  70. Passmore SR, Kisicki A, Gilmore-Bykovskyi A, Green-Harris G, Edwards DF. “There’s not much we can do…” Researcher-level barriers to the inclusion of underrepresented participants in translational research. Journal of Clinical and Translational Science. 2022;6:e4. doi: 10.1017/cts.2021.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, Dekermanjian JP, Jolley SE, Kahn MG, Kostka K, McMurry JA, Moffitt R, Walden A, Chute CG, Haendel MA, N3C Consortium Identifying who has long COVID in the USA: a machine learning approach using N3C data. The Lancet. Digital Health. 2022;4:e532–e541. doi: 10.1016/S2589-7500(22)00048-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, Hill E, Kelly E, Kostka K, Loomba J, McMurry JA, Wong R, Bennett TD, Moffitt R, Chute CG, Haendel M, N3C Consortium. RECOVER Consortium Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Medicine. 2023;21:58. doi: 10.1186/s12916-023-02737-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. PLRC Patient Led Research Collaborative – for Long COVID. 2023. [July 19, 2023]. https://patientresearchcovid19.com/
  74. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Frontiers in Microbiology. 2021;12:698169. doi: 10.3389/fmicb.2021.698169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. RECOVER Initiative RECOVER January listening session: understanding long COVID across communities of color. 2022. [January 21, 2022]. https://videocast.nih.gov/watch=44524
  76. Rees CA, Stewart AM, Mehta S, Avakame E, Jackson J, McKay J, Portillo EN, Michelson KA, Duggan CP, Fleegler EW. Reporting of participant race and ethnicity in published US Pediatric Clinical Trials from 2011 to 2020. JAMA Pediatrics. 2022;176:e220142. doi: 10.1001/jamapediatrics.2022.0142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, de Almeida APFG, Callegari ED, Neto ADF, Savassi LCM, Simplicio MIC, Ribeiro LB, Oliveira R, Harari O, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Rowland-Yeo K, Guyatt GH, Boulware DR, Rayner CR, Mills EJ, TOGETHER Investigators Effect of early treatment with Ivermectin among Patients with Covid-19. The New England Journal of Medicine. 2022;386:1721–1731. doi: 10.1056/NEJMoa2115869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Resolve to Save Lives, V. S Public Awareness of Long Covid & Motivation to get Vaccinated. 2021. [September 25, 2022]. https://preventepidemics.org/wp-content/uploads/2021/06/Report_Long_COVID_Survey.pdf
  79. Rowland C. Patients with long covid symptoms face tough disability benefit fights—The Washington Post. 2022. [March 8, 2022]. https://www.washingtonpost.com/business/2022/03/08/long-covid-disability-benefits/
  80. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM, National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Steingrub J, Smithline H, Tiru B, Tidswell M, Kozikowski L, Thornton-Thompson S, De Souza L, Hou P, Baron R, Massaro A, Aisiku I, Fredenburgh L, Seethala R, Johnsky L, Riker R, Seder D, May T, Baumann M, Eldridge A, Lord C, Shapiro N, Talmor D, O’Mara T, Kirk C, Harrison K, Kurt L, Schermerhorn M, Banner-Goodspeed V, Boyle K, Dubosh N, Filbin M, Hibbert K, Parry B, Lavin-Parsons K, Pulido N, Lilley B, Lodenstein C, Margolin J, Brait K, Jones A, Galbraith J, Peacock R, Nandi U, Wachs T, Matthay M, Liu K, Kangelaris K, Wang R, Calfee C, Yee K, Hendey G, Chang S, Lim G, Qadir N, Tam A, Beutler R, Levitt J, Wilson J, Rogers A, Vojnik R, Roque J, Albertson T, Chenoweth J, Adams J, Pearson S, Juarez M, Almasri E, Fayed M, Hughes A, Hillard S, Huebinger R, Wang H, Vidales E, Patel B, Ginde A, Moss M, Baduashvili A, McKeehan J, Finck L, Higgins C, Howell M, Douglas I, Haukoos J, Hiller T, Lyle C, Cupelo A, Caruso E, Camacho C, Gravitz S, Finigan J, Griesmer C, Park P, Hyzy R, Nelson K, McDonough K, Olbrich N, Williams M, Kapoor R, Nash J, Willig M, Ford H, Gardner-Gray J, Ramesh M, Moses M, Ng Gong M, Aboodi M, Asghar A, Amosu O, Torres M, Kaur S, Chen JT, Hope A, Lopez B, Rosales K, Young You J, Mosier J, Hypes C, Natt B, Borg B, Salvagio Campbell E, Hite RD, Hudock K, Cresie A, Alhasan F, Gomez-Arroyo J, Duggal A, Mehkri O, Hastings A, Sahoo D, Abi Fadel F, Gole S, Shaner V, Wimer A, Meli Y, King A, Terndrup T, Exline M, Pannu S, Robart E, Karow S, Hough C, Robinson B, Johnson N, Henning D, Campo M, Gundel S, Seghal S, Katsandres S, Dean S, Khan A, Krol O, Jouzestani M, Huynh P, Weissman A, Yealy D, Scholl D, Adams P, McVerry B, Huang D, Angus D, Schooler J, Moore S, Files C, Miller C, Gibbs K, LaRose M, Flores L, Koehler L, Morse C, Sanders J, Langford C, Nanney K, MdalaGausi M, Yeboah P, Morris P, Sturgill J, Seif S, Cassity E, Dhar S, de Wit M, Mason J, Goodwin A, Hall G, Grady A, Chamberlain A, Brown S, Bledsoe J, Leither L, Peltan I, Starr N, Fergus M, Aston V, Montgomery Q, Smith R, Merrill M, Brown K, Armbruster B, Harris E, Middleton E, Paine R, Johnson S, Barrios M, Eppensteiner J, Limkakeng A, McGowan L, Porter T, Bouffler A, Leahy JC, deBoisblanc B, Lammi M, Happel K, Lauto P, Self W, Casey J, Semler M, Collins S, Harrell F, Lindsell C, Rice T, Stubblefield W, Gray C, Johnson J, Roth M, Hays M, Torr D, Zakaria A, Schoenfeld D, Thompson T, Hayden D, Ringwood N, Oldmixon C, Ulysse C, Morse R, Muzikansky A, Fitzgerald L, Whitaker S, Lagakos A, Brower R, Reineck L, Aggarwal N, Bienstock K, Freemer M, Maclawiw M, Weinmann G, Morrison L, Gillespie M, Kryscio R, Brodie D, Zareba W, Rompalo A, Boeckh M, Parsons P, Christie J, Hall J, Horton N, Zoloth L, Dickert N, Diercks D. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with COVID-19: a Randomized Clinical Trial. JAMA. 2020;324:2165–2176. doi: 10.1001/jama.2020.22240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Shaffer L. Lots of long COVID treatment leads, but few are proven. PNAS. 2022;119:e2213524119. doi: 10.1073/pnas.2213524119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Shaw BH, Stiles LE, Bourne K, Green EA, Shibao CA, Okamoto LE, Garland EM, Gamboa A, Diedrich A, Raj V, Sheldon RS, Biaggioni I, Robertson D, Raj SR. The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey. Journal of Internal Medicine. 2019;286:438–448. doi: 10.1111/joim.12895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Sherif ZA, Gomez C, Conners T, Timothy H, Reeves BW. Disease and tissue-injury mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC) eLife. 2022;12:e86002. doi: 10.7554/eLife.86002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Slovic P, Peters E. Risk perception and affect. Current Directions in Psychological Science. 2006;15:322–325. doi: 10.1111/j.1467-8721.2006.00461.x. [DOI] [Google Scholar]
  85. Snyder JE, Upton RD, Hassett TC, Lee H, Nouri Z, Dill M. Black representation in the Primary Care Physician workforce and its Association with Population Life Expectancy and Mortality Rates in the US. JAMA Network Open. 2023;6:e236687. doi: 10.1001/jamanetworkopen.2023.6687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Social Determinants of Health Social Determinants of Health. 2022. [September 11, 2022]. https://health.gov/healthypeople/priority-areas/social-determinants-health
  87. Solve M.E The Solve Long Covid Initiative. Solve ME/CFS Initiative. 2023. [July 19, 2023]. https://solvecfs.org/the-solve-long-covid-initiative/
  88. Solve M.E. Advocacy Week Solve ME/CFS Initiative. 2021. [September 25, 2022]. https://solvecfs.org/advocacy/advocacy-week/
  89. Sperling L. Silos in healthcare are bad for us. Here’s the cure. World Economic Forum. 2020. [November 14, 2020]. https://www.weforum.org/agenda/2020/11/healthcare-silos-are-bad-for-us-heres-the-cure/
  90. Stead Sellers F. How long covid could change the way we think about disability. Washington Post. 2022. [July 6, 2022]. https://www.washingtonpost.com/health/2022/06/06/long-covid-disability-advocacy/
  91. Suran M. Long COVID Linked With Unemployment in New Analysis. JAMA. 2023;329:701–702. doi: 10.1001/jama.2023.0157. [DOI] [PubMed] [Google Scholar]
  92. Tanne JH. Covid-19: US studies show racial and ethnic disparities in long covid. BMJ. 2023;380:535. doi: 10.1136/bmj.p535. [DOI] [PubMed] [Google Scholar]
  93. The Ehlers-Danlos Society Home. The Ehlers Danlos Society. 2023. [July 19, 2023]. https://www.ehlers-danlos.com/
  94. The Rockefeller Foundation. PPI. COVID Collaborative. Colton Foundation Getting to and Sustaining the Next Normal, A Roadmap for LIving with COVID. 2022. [August 12, 2022]. https://www.rockefellerfoundation.org/wp-content/uploads/2022/03/Getting-to-and-Sustaining-the-Next-Normal-A-Roadmap-for-Living-with-Covid-Report-Final.pdf
  95. U.S. Centers for Disease Control and Prevention Provisional COVID-19 Deaths by Sex and Age | Data | Centers for Disease Control and Prevention. 2023. [July 6, 2023]. https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-by-Sex-and-Age/9bhg-hcku
  96. U.S. Department of Health and Human Services Long COVID Reports. 2022a. [August 5, 2022]. https://mcusercontent.com/83b4b5eb5ee2dedf97f02d08e/files/22ef5e69-9535-a2ef-39fe-d1c4fb2184a0/Internal_Key_Messages_and_QAs_for_Federal_Partners_FINAL.pdf
  97. U.S. Department of Health and Human Services National Research Action Plan. 2022b. [August 17, 2022]. https://www.covid.gov/assets/files/National-Research-Action-Plan-on-Long-COVID-08012022.pdf
  98. U.S. Society Security Administration Disabled-worker statistics. 2022. [August 5, 2022]. https://www.ssa.gov/oact/STATS/dibStat.html
  99. Wadman M. Long Covid is a ‘national crisis.’ So why are grants taking so long to get? 2022. [June 10, 2022]. https://www.science.org/content/article/long-covid-national-crisis-so-why-are-grants-taking-so-long-get
  100. Wagner Mery M. Mobilizing Long COVID Awareness to Better Support People with Acquired Disabilities. 2022. [April 29, 2022]. http://blog.petrieflom.law.harvard.edu/2022/04/29/mobilizing-long-covid-awareness-to-better-support-people-with-acquired-disabilities/
  101. White SE. A review of big data in health care: challenges and opportunities. Open Access Bioinformatics. 2014;6:13–18. doi: 10.2147/OAB.S50519. [DOI] [Google Scholar]
  102. Wilkins CH, Williams M, Kaur K, DeBaun MR. Academic Medicine’s Journey Toward Racial Equity Must Be Grounded in History: Recommendations for Becoming an Antiracist Academic Medical Center. Academic Medicine. 2021;96:1507–1512. doi: 10.1097/ACM.0000000000004374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. World Health Organization Coronavirus disease (COVID-19): Hydroxychloroquine. 2023. [March 28, 2023]. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-hydroxychloroquine
  104. Yearby R, Clark B, Figueroa JF. Structural Racism In Historical And Modern US Health Care Policy. Health Affairs (Project Hope) 2022;41:187–194. doi: 10.1377/hlthaff.2021.01466. [DOI] [PubMed] [Google Scholar]
  105. Yong E. Long-Haulers Are Redefining COVID-19. 2020. [August 19, 2020]. https://www.theatlantic.com/health/archive/2020/08/long-haulers-covid-19-recognition-support-groups-symptoms/615382/
  106. Yong E. Even Health-Care Workers With Long COVID Are Being Dismissed. The Atlantic. 2021. [November 24, 2021]. https://www.theatlantic.com/health/archive/2021/11/health-care-workers-long-covid-are-being-dismissed/620801/

Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

RESOURCES